FY2026 EPS Estimates for enGene Boosted by Leerink Partnrs

enGene Holdings Inc. (NASDAQ:ENGN) – Analysts at Leerink Partnrs upped their FY2026 earnings estimates for shares of enGene in a report issued on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings per share of ($1.85) for the year, up from their previous forecast of ($1.89). The consensus estimate for enGene’s current full-year earnings is ($1.57) per share. Leerink Partnrs also issued estimates for enGene’s FY2027 earnings at ($1.74) EPS and FY2028 earnings at ($0.45) EPS.

A number of other research firms also recently commented on ENGN. Raymond James initiated coverage on shares of enGene in a report on Wednesday, November 27th. They set an “outperform” rating and a $23.00 price objective for the company. HC Wainwright began coverage on shares of enGene in a report on Monday, December 23rd. They set a “buy” rating and a $25.00 price target for the company. JMP Securities reissued a “market outperform” rating and set a $18.00 price target on shares of enGene in a report on Monday, December 23rd. Finally, Citizens Jmp raised shares of enGene to a “strong-buy” rating in a report on Monday, November 18th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $29.78.

enGene Price Performance

NASDAQ:ENGN opened at $7.16 on Friday. The company has a 50-day moving average of $7.36 and a 200-day moving average of $7.52. The company has a market capitalization of $316.59 million, a price-to-earnings ratio of -12.34 and a beta of -0.65. enGene has a 52 week low of $4.42 and a 52 week high of $18.40. The company has a debt-to-equity ratio of 0.08, a quick ratio of 16.87 and a current ratio of 16.87.

enGene (NASDAQ:ENGN) last released its quarterly earnings data on Thursday, December 19th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ENGN. Franklin Resources Inc. lifted its position in shares of enGene by 48.7% in the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock worth $7,854,000 after purchasing an additional 389,918 shares in the last quarter. Point72 Asset Management L.P. lifted its position in shares of enGene by 1,410.3% in the third quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock worth $4,376,000 after purchasing an additional 619,100 shares in the last quarter. Finally, Wolverine Asset Management LLC bought a new stake in shares of enGene in the third quarter worth $37,000. Institutional investors and hedge funds own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.